Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

Document first published:: 9 July 2020
Page updated:: 20 April 2026
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy

Rituximab is recommended to be available as a treatment option through routine commissioning for refractory SLE in adults and post-pubescent children within the criteria set out in this document.

Document

$Clinical commissioning policy: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Clinical commissioning policy: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
206 KB
12 pages

Document

$Clinical panel report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Clinical panel report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
23 KB
2 pages

Document

$CPAG summary report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

CPAG summary report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
145 KB
11 pages

Document

$Evidence report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Evidence report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
56 KB
2 pages

Document

$Evidence report 2: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Evidence report 2: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
20 KB
2 pages

Document

$Evidence review: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Evidence review: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
704 KB
35 pages

Document

$Public consultation report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Public consultation report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
87 KB
6 pages

Document

$Public engagement report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children$

Public engagement report: Rituximab for refractory Systemic Lupus Erythematosus (SLE) in adults and post-pubescent children

PDF
43 KB
3 pages

Cookies on the NHS England website